Clene to File Accelerated Approval NDA for ALS Drug CNM-Au8 After Successful FDA Meeting
CLNN has more than doubled off its 52-week low of $2.28.
Summary
Clene Inc. announced a successful meeting with the FDA, confirming the company's intent to file an Accelerated Approval New Drug Application (NDA) for its ALS drug candidate, CNM-Au8. The FDA indicated that CNM-Au8 data may support an NDA under the accelerated pathway and acknowledged neurofilament light chain (NfL) as a potential surrogate endpoint. This is a highly significant development for Clene, particularly in light of the company's previously disclosed 'going concern' doubts in its last 10-K, which also highlighted promising clinical data for CNM-Au8. This regulatory progress provides a clear path towards potential market approval and future revenue, which could significantly de-risk the company's financial outlook. The company plans to submit the NDA in Q3 2026, supported by Phase 2 HEALEY ALS and RESCUE-ALS trial data. Investors will now closely watch the NDA submission and subsequent FDA review process.
At the time of this announcement, CLNN was trading at $6.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.3M. The 52-week trading range was $2.28 to $13.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.